Brokerages Anticipate Avenue Therapeutics Inc (ATXI) to Announce -$0.47 EPS

Analysts expect that Avenue Therapeutics Inc (NASDAQ:ATXI) will announce earnings of ($0.47) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Avenue Therapeutics’ earnings. The lowest EPS estimate is ($0.62) and the highest is ($0.38). Avenue Therapeutics reported earnings per share of ($0.63) during the same quarter last year, which suggests a positive year over year growth rate of 25.4%. The company is expected to issue its next earnings results on Thursday, March 7th.

According to Zacks, analysts expect that Avenue Therapeutics will report full year earnings of ($2.23) per share for the current fiscal year, with EPS estimates ranging from ($2.35) to ($2.10). For the next fiscal year, analysts forecast that the company will report earnings of ($1.98) per share, with EPS estimates ranging from ($2.72) to ($1.55). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Avenue Therapeutics.

ATXI has been the subject of a number of recent analyst reports. ValuEngine raised Avenue Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Oppenheimer set a $8.00 target price on Avenue Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Avenue Therapeutics in a research report on Wednesday, August 15th.

Shares of NASDAQ:ATXI opened at $5.39 on Friday. Avenue Therapeutics has a fifty-two week low of $2.08 and a fifty-two week high of $6.00. The stock has a market capitalization of $57.47 million, a price-to-earnings ratio of -3.05 and a beta of -2.35.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

Further Reading: What is a Stop Order?

Get a free copy of the Zacks research report on Avenue Therapeutics (ATXI)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Avenue Therapeutics (NASDAQ:ATXI)

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply